Patents by Inventor Rowena CHRISTENSEN

Rowena CHRISTENSEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds as diacylglycerol acyltransferase inhibitors
    Patent number: 9242929
    Abstract: This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection and acne or other skin disorders.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: January 26, 2016
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Siegfried Benjamin Christensen, IV, Rowena Christensen, Donghui Qin, Hemant Joshi, Raghuram S. Tangirala
  • Novel Compounds as Diacylglycerol Acyltransferase Inhibitors
    Publication number: 20150307445
    Abstract: This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection and acne or other skin disorders.
    Type: Application
    Filed: May 18, 2012
    Publication date: October 29, 2015
    Applicant: GlaxoSmith Kline Intellectual Property (No.2) Limited
    Inventor: Rowena CHRISTENSEN